SAN DIEGO, May 12, 2015 (GLOBE NEWSWIRE) -- Genelux Corporation, a clinical-stage biopharmaceutical company focused on the development of vaccinia virus for oncolytic immunotherapy, today announced that two posters supporting the ongoing clinical development of its lead clinical candidate GL-ONC1 will be presented at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2 in Chicago, IL.
Lead investigators from Memorial Sloan Kettering Cancer Center and UC San Diego Moores Cancer Center will present findings from two separate Phase I clinical trials evaluating GL-ONC1 in the treatment of head and neck cancer and malignant pleural effusion, a condition in which fluid builds up between the tissues that line the lungs and the chest.
"Nearly 90 patients with various tumor types have been dosed with GL-ONC1 in four clinical trials to date, demonstrating a favorable safety profile and evidence of anti-tumor activity," commented Thomas Zindrick, President & CEO of Genelux Corporation. "Following the recent FDA panel meeting that ruled in favor of Amgen's herpes virus for treatment of malignant melanoma, increased attention is being placed on oncolytic immunotherapies. We look forward to sharing results of our two Phase I trials separately evaluating GL-ONC1 in head and neck and mesothelioma/lung cancers with the global oncology community at ASCO and further validating this cancer therapy as a promising treatment modality. We believe GL-ONC1 has the potential to effectively treat a range of cancers by precisely selecting and destroying cancer cells without harming healthy tissues or organs and by awakening the immune system for long-term immunotherapy."
Details of the two abstracts accepted for poster presentation are outlined below:
|-- Abstract 6026 / Poster 349: Phase I trial of intravenous attenuated vaccinia virus (GL-ONC1) with concurrent chemoradiotherapy (CRT) for locoregionally advanced head and neck carcinoma.|
|First / Presenting Author:||Loren K. Mell, M.D., UC San Diego Moores Cancer Center|
|Poster Session:||Head and Neck Cancer|
|Date, Time:||Saturday, May 30; 1:15 PM - 4:45 PM|
|Location:||S Hall A, McCormick Place|
|-- Abstract 7559 / Poster 307: Phase I study of intra-pleural administration of GL-ONC1, an oncolytic vaccinia virus, in patients with malignant pleural effusion.|
|First / Presenting Author:||Lee M. Krug, MD, Memorial Sloan Kettering Cancer Center|
|Poster Session:||Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers|
|Date, Time:||Monday, June 1; 8:00 - 11:30 AM|
|Location:||S Hall A, McCormick Place|
GL-ONC1, the company's lead oncology product candidate, is an attenuated vaccinia virus (Lister strain). Vaccinia virus, a non-pathogenic virus, was used safely in millions of people as the vaccine against smallpox. Scientists at Genelux have modified this virus to increase its safety, tumor selectivity and anti-tumor activity without limiting its ability to replicate in and kill cancer cells. Such virus-mediated oncolysis triggers immune activation, for long-term immunotherapy against cancer. GL-ONC1 is currently under evaluation in multiple Phase 1 and 1/2 clinical trials in the US and Europe. Clinical results have shown GL-ONC1 is well tolerated with minimal toxicity and exhibits evidence of anti-tumor activity.
About Genelux Corporation
Headquartered in San Diego, California, Genelux Corporation is a privately-held, clinical-stage biopharmaceutical company dedicated to fundamentally changing the way in which cancer is diagnosed and treated. The company has developed a proprietary, vaccinia virus-based technology platform. Such platform can also be engineered to insert specific genes for delivery and amplification of therapeutic and diagnostic proteins. For more information please visit www.genelux.com.